Latest news
FDA Approves Oveporexton for NT1, Grants RMAT Designation to Sasineprocel in PD, Emerging Literature in Spinal Muscular Atrophy - NeurologyLiveNeurologyLive · Sun, 09 Aug 2026 16:12:15 GMTFDA Grants RMAT Designation to Sasineprocel for Parkinson Disease - NeurologyLiveNeurologyLive · Tue, 04 Aug 2026 22:35:24 GMTFDA grants OCU410 regenerative medicine advanced therapy designation for geographic atrophy - AllSciAllSci · Fri, 31 Jul 2026 12:34:41 GMTFDA grants Aspen RMAT designation for cell therapy in Parkinson's disease - AllSciAllSci · Fri, 31 Jul 2026 12:19:16 GMTFDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL - Lymphoma HubLymphoma Hub · Thu, 30 Jul 2026 19:46:39 GMTFDA Grants Fast Track and RMAT Designations to Cema-Cel in LBCL - Targeted OncologyTargeted Oncology · Thu, 30 Jul 2026 07:00:00 GMTOcugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.Ocugen, Inc. · Wed, 29 Jul 2026 16:15:30 GMTFDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL - OncLiveOncLive · Wed, 29 Jul 2026 07:00:00 GMT